Cancer Molecular Pathology, School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast, Q4222, Australia.
Endocr Pathol. 2017 Sep;28(3):213-227. doi: 10.1007/s12022-017-9484-5.
The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as "Tumours of the adrenal cortex" and "Tumours of the adrenal medulla and extra-adrenal paraganglia." Tumours of the adrenal cortex are classified as cortical carcinoma, cortical adenoma, sex cord stromal tumours, adenomatoid tumour, mesenchymal and stromal tumours (myelolipoma and schwannoma), haematological tumours, and secondary tumours. Amongst them, schwannoma and haematological tumours are newly documented. The major updates in adrenal cortical lesions are noted in the genetics of the cortical carcinoma and cortical adenoma based on the data from The Cancer Genome Atlas (TCGA). Also, a system for differentiation of oncocytoma from oncocytic cortical carcinoma is adopted. Tumours of the adrenal medulla and extra-adrenal paraganglia comprise pheochromocytoma, paraganglioma (head and neck paraganglioma and sympathetic paraganglioma), neuroblastic tumours (neuroblastoma, nodular ganglioneuroblastoma, intermixed ganglioneuroblastoma, and ganglioneuroma), composite pheochromocytoma, and composite paraganglioma. In this group, neuroblastic tumours are newly included in the classification. The clinical features, histology, associated pathologies, genetics, and predictive factors of pheochromocytoma and paraganglioma are the main changes introduced in this chapter of WHO classification of endocrine tumours. The term "metastatic pheochromocytoma/paraganglioma" is used to replace "malignant pheochromocytoma/paraganglioma." Also, composite pheochromocytoma and composite paraganglioma are now documented in separate sections instead of one. Overall, the new classification incorporated new data on pathology, clinical behaviour, and genetics of the adrenal tumours that are important for current management of patients with these tumours.
世界卫生组织(WHO)第四版内分泌肿瘤分类包含了大量关于肾上腺肿瘤的新发现。这些肿瘤在两个章节中呈现,分别标记为“肾上腺皮质肿瘤”和“肾上腺髓质和肾上腺外副神经节肿瘤”。肾上腺皮质肿瘤分为皮质癌、皮质腺瘤、性索间质肿瘤、腺肌瘤、间叶和基质肿瘤(髓样脂肪瘤和神经鞘瘤)、血液肿瘤和继发性肿瘤。其中,神经鞘瘤和血液肿瘤是新记录的。基于癌症基因组图谱(TCGA)的数据,在皮质癌和皮质腺瘤的遗传学方面有了主要更新。此外,还采用了一种区分嗜铬细胞瘤和嗜酸性皮质癌的系统。肾上腺髓质和肾上腺外副神经节肿瘤包括嗜铬细胞瘤、副神经节瘤(头颈部副神经节瘤和交感副神经节瘤)、神经母细胞瘤(神经母细胞瘤、结节性节神经母细胞瘤、混合性节神经母细胞瘤和节神经细胞瘤)、复合嗜铬细胞瘤和复合副神经节瘤。在这一组中,神经母细胞瘤被新纳入分类。本版 WHO 内分泌肿瘤分类主要介绍了嗜铬细胞瘤和副神经节瘤的临床特征、组织学、相关病理学、遗传学和预测因素。“转移性嗜铬细胞瘤/副神经节瘤”一词取代了“恶性嗜铬细胞瘤/副神经节瘤”。此外,复合嗜铬细胞瘤和复合副神经节瘤现在分别记录在单独的部分,而不是一个部分。总体而言,新分类纳入了关于病理学、临床行为和遗传学的新数据,这些数据对目前这些肿瘤患者的管理非常重要。